Artrya Ltd (ASX: AYA) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Artrya Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$516.93 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
151.21 million
Earnings per share
-0.182
Dividend per share
N/A
Year To Date Return
-26.54%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Artrya Ltd (ASX: AYA)
Latest News
Healthcare Shares
Two booming ASX healthcare stocks investors should be buying the dip on
Opinions
1 ASX blue-chip share and one small-cap share to buy in 2026: experts
Technology Shares
This ASX tech stock is jumping 6% on big US AI news
AI Stocks
Up 752% in one year! This roaring ASX AI stock just hit all-time highs on major revenue milestone
Share Gainers
Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today
AI Stocks
Why is this ASX AI share jumping 11% today?
Small Cap Shares
These 2 ASX small-cap shares have big potential for returns
Share Market News
5 ASX artificial intelligence (AI) shares to watch in 2025
IPOs
New artificial intelligence ASX share rockets 13% on debut
Technology Shares
Move over Appen: A new artificial intelligence stock to list on the ASX
Frequently Asked Questions
-
No, Artrya has not yet paid dividends to shareholders.
-
The company, founded in 2019 in Perth, listed on the ASX on 26 November 2021.
AYA ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Artrya Ltd
Artrya Ltd (ASX: AYA) is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. Artrya’s Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.
The Perth-based company says the technology will revolutionise the speed and accuracy of coronary artery disease diagnosis.
AYA Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $3.27 | $-0.11 | -3.25% | 548,773 | $3.23 | $3.30 | $3.06 |
| 05 Feb 2026 | $3.38 | $-0.08 | -2.31% | 671,757 | $3.46 | $3.51 | $3.35 |
| 04 Feb 2026 | $3.46 | $-0.19 | -5.21% | 945,647 | $3.68 | $3.75 | $3.28 |
| 03 Feb 2026 | $3.65 | $0.09 | 2.53% | 286,198 | $3.58 | $3.71 | $3.51 |
| 02 Feb 2026 | $3.56 | $0.03 | 0.85% | 876,486 | $3.42 | $3.57 | $3.37 |
| 30 Jan 2026 | $3.53 | $-0.21 | -5.61% | 1,232,607 | $3.80 | $3.82 | $3.43 |
| 29 Jan 2026 | $3.74 | $-0.13 | -3.36% | 641,237 | $3.90 | $3.92 | $3.57 |
| 28 Jan 2026 | $3.87 | $-0.22 | -5.38% | 572,721 | $4.08 | $4.12 | $3.79 |
| 27 Jan 2026 | $4.09 | $-0.13 | -3.08% | 284,544 | $4.24 | $4.24 | $4.04 |
| 23 Jan 2026 | $4.22 | $0.07 | 1.69% | 273,178 | $4.15 | $4.25 | $4.00 |
| 22 Jan 2026 | $4.15 | $0.14 | 3.49% | 342,272 | $4.00 | $4.15 | $3.87 |
| 21 Jan 2026 | $4.01 | $-0.09 | -2.20% | 1,083,569 | $4.01 | $4.05 | $3.80 |
| 20 Jan 2026 | $4.10 | $-0.01 | -0.24% | 464,007 | $4.12 | $4.12 | $3.90 |
| 19 Jan 2026 | $4.11 | $-0.25 | -5.73% | 880,110 | $4.43 | $4.47 | $4.08 |
| 16 Jan 2026 | $4.36 | $0.35 | 8.73% | 684,214 | $4.01 | $4.38 | $3.94 |
| 15 Jan 2026 | $4.01 | $-0.17 | -4.07% | 427,267 | $4.23 | $4.23 | $4.01 |
| 14 Jan 2026 | $4.18 | $-0.06 | -1.42% | 865,338 | $4.22 | $4.34 | $4.00 |
| 13 Jan 2026 | $4.24 | $-0.22 | -4.93% | 842,582 | $4.46 | $4.46 | $4.18 |
| 12 Jan 2026 | $4.46 | $-0.09 | -1.98% | 650,813 | $4.60 | $4.65 | $4.44 |
| 09 Jan 2026 | $4.55 | $-0.03 | -0.66% | 243,422 | $4.60 | $4.62 | $4.50 |
| 08 Jan 2026 | $4.58 | $-0.16 | -3.38% | 396,440 | $4.71 | $4.71 | $4.52 |
| 07 Jan 2026 | $4.74 | $-0.18 | -3.66% | 629,545 | $4.95 | $5.03 | $4.67 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Bernard (Bernie) William Ridgeway | Non-Executive ChairmanNon-Executive Director | Feb 2021 |
Mr Ridgeway brings a wealth of corporate experience to Artrya, including 38 years in private and ASX-listed companies, spending most of that time in the role of Managing Director. Bernie was Managing Director of the ASX listed top 300 company Imdex Limited (Imdex) for 20 years, retiring in July 2020.
|
| Dr Jacque Sokolov | Non-Executive Director | Aug 2022 |
Dr Sokolov has experience across all aspects of the US healthcare industry, in particular healthcare delivery, biotechnology, and regulatory clearance. He was appointed Artrya Clinical Advisory Board Chair in January 2022 and Chairman and President of Artrya USA Inc. in March 2022. He is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company. He currently serves on multiple public, private and not-for-profit healthcare boards.
|
| Ms Catherine (Kate) Hill | Non-Executive Director | Feb 2023 |
Ms Hill is a non-executive director of ASX listed companies and has experience in both technology companies and the biotech and medical devices sectors. In addition, she has experience of other listing exchanges including Nasdaq (US) and AIM (UK). She previously spent 20 years as an audit partner at Deloitte, serving both ASX-listed and privately owned clients. She has worked in regulated environments, including assisting with Initial Public Offerings, capital raising, and general compliance, as well as operating in an audit environment.
|
| Mr Kevin R Hart | Company Secretary | Oct 2022 |
-
|
| Kevin R Hart | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 18,325,583 | 12.37% |
| HSBC Custody Nominees (Australia) Limited | 8,696,205 | 5.87% |
| Ms Erika Henriette Konstantopoulos <Iemk Family A/C> | 7,260,000 | 4.90% |
| Ubs Nominees Pty Ltd | 7,059,963 | 4.77% |
| Mr John Barrington <Bht Family A/C> | 6,950,103 | 4.69% |
| BNP Paribas Noms Pty Ltd | 5,216,414 | 3.52% |
| Richcab Pty Ltd | 4,878,115 | 3.29% |
| Netwealth Investments Limited <Wrap Services A/C> | 3,544,879 | 2.39% |
| Mutual Trust Pty Ltd | 3,163,249 | 2.14% |
| Keeble Nominees Pty Ltd <Ridgeway Self Managed Super Fund A/C> | 3,121,025 | 2.11% |
| Zanya Nominees Pty Ltd <Jls Superannuation Fund A/C> | 2,845,636 | 1.92% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 2,712,620 | 1.83% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 2,191,576 | 1.48% |
| J P Morgan Nominees Australia Pty Limited | 1,967,765 | 1.33% |
| Healthliant Ventures Llc | 1,797,760 | 1.21% |
| Mr Paul Ernest Neilsen & Mrs Julie Louise Neilsen | 1,732,361 | 1.17% |
| Lightview Asset Pty Ltd | 1,598,175 | 1.08% |
| Ian Sandover & Associates Pty Ltd Handover Super A/C> | 1,555,000 | 1.05% |
| Gaziton Pty Ltd <The Miller Super Fund A/C> | 1,500,000 | 1.01% |
| Pgta Family Pty Ltd <Pgta Family A/C> | 1,300,000 | 0.88% |
